Other treatments, have been used in DBA over the last 30 years. These drugs appear to be largely ineffective and there is currently no evidence that any of these has a major role in the management of DBA. (Vlachos et al, 2008; Geller et al, 1975; Dunbar et al, 1991; Fiorillo et al, 1991; Niemeyer et al, 1991; Gomez-Almaguer & Gonzalez-Llano, 1992; Sumimoto et al, 1992; Bejaoui et al, 1993; Gillio et al, 1993a, 1993b; Bastion et al, 1994; Brown et al, 1994; Olivieri et al, 1994; Ozsoylu, 1994; Ball et al, 1995; Bernini et al, 1995; Buchanan, 2001; Alter, 2003)

Summary of Alternative Therapies from the International Clinical Care Consensus Document:

 

Treatments Number of Patients Response
Androgens >100 20%
High dose corticosteroids 12 7
8 3 complete, 1 partial
9 5 all transient
Erythropoietin 10 1 transient
Interleukin-3 100 10%
Cyclosporine ± prednisone 20 (with steroids) 50% all transient
10 (CSA alone) 2 sustained response
Metoclopromide 9 1 complete
2 partial on steroid taper
1 1 complete
33 2 partial
Valproic acid 1 1 complete
Leucine 1 1 complete
Other (6-MP, cylcophosphamide, Vincristine, stem cell factor, PIXY 321, IVIG) Largely ineffective